* This innovative platform technology, with exceptional scalability, has been recognized as highl...
- First global out-licensing deal since founding — tangible return on new drug development investme...
* Emerging as a next-generation vaccine amidst global resurgence of COVID-19 * Expanding v ariou...
- Preparing for Phase 2 Global Trials of a?Ferritin Platform-Based Virus-Like Particle Universal Co...
* Introduction of a Universal Coronavirus Vaccine: A robust cross-immunity effect to combat virus...
* Pioneering Korea's ARPA-H Project: Focused on mRNA Vaccine Room-Temperature Storage and Extra-...
- Seminar presentation at the invitation of Dx&Vx and Coree Group SEOUL, South Korea, Aug. 26, 2024...
* Confirmation of effects compared to global late-stage clinical trials * Accelerating the devel...
* To be registered as an official research organization by the National Assembly Secretariat... ...
SEOUL, South Korea, Jan. 3, 2024 /PRNewswire/ -- Chong-Yoon Lim, Chairman of COREE group, President...
- Possessing human genome and microbiome data in all clinical stages - Becoming a global bio-healthc...
- Final stage in licensing OVM-200 from Oxford?Vacmedix in the UK - DxVx plans to proceed its own cl...
* National Project converging semiconductor and biotechnology SEOUL, South Korea, June 9, 2023 /P...
- Pipeline development updates on age related macular degeneration, dry eye disease and atopic derm...
- Reorganizing the global sales networks and enhancing its capabilities to get global approvals for...
SEOUL, South Korea, March 30, 2023 /PRNewswire/ -- DXVX announces that its affiliated company Oxfor...
SEOUL, South Korea, Oct. 13, 2022 /PRNewswire/ -- According to International Diabetes Federation, a...